Skip to main content

Medicus Pharma Ltd.

corporate_fare Company Profile

Medicus Pharma Ltd.

Medicus Pharma Ltd., a biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets in the United States. It is developing SKNJCT-003, which is in Phase 2 study for the treatment of basal cell carcinoma of the skin. Medicus Pharma Ltd. has a strategic collaboration with the Gorlin Syndrome Alliance to access to SKINJECT in Patients with Gorlin Syndrome. The company was formerly known as Interactive Capital Partners Corporation and changed its name to Medicus Pharma Ltd. in September 2023. The company was incorporated in 2008 and is headquartered in Conshohocken, Pennsylvania.

Exchange: NASDAQSector: Life Sciences

show_chartPrice Chart

Loading chart...

feed MDCX - Latest Insights

MDCX
Apr 24, 2026, 5:27 PM EDT
Filing Type: 8-K
Importance Score:
9
Medicus Pharma Faces Nasdaq Delisting, Discloses $11.5M Raised in Highly Dilutive ATM Program
Sentiment: Negative
View Wiseek Article
MDCX
Apr 23, 2026, 5:10 PM EDT
Filing Type: 424B3
Importance Score:
9
Medicus Pharma Expands At-The-Market Offering to $50M, Signaling Extreme Dilution Risk Amidst Financial Distress
Sentiment: Negative
View Wiseek Article
MDCX
Apr 21, 2026, 6:01 AM EDT
Filing Type: PRE 14A
Importance Score:
8
Medicus Pharma Proposes Reverse Stock Split Up to 1:50 to Avoid Nasdaq Delisting
Sentiment: Negative
View Wiseek Article
MDCX
Apr 06, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Medicus Pharma Submits Optimized Phase 2 Protocol for Teverelix, Targeting $2B Market with Capital-Efficient Design
Sentiment: Positive
View Wiseek Article
MDCX
Mar 26, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Medicus Pharma's SkinJect Phase 2 Hits 80% ORR, Aims to Reduce Skin Cancer Surgeries
Sentiment: Positive
View Wiseek Article
MDCX
Mar 25, 2026, 4:49 PM EDT
Filing Type: 424B3
Importance Score:
8
Medicus Pharma Discloses Going Concern Warning, Reports Heavy Dilution and Positive Phase 2 Data in Annual Filing
Sentiment: Negative
View Wiseek Article
MDCX
Mar 25, 2026, 4:30 PM EDT
Source: Access Newswire
Importance Score:
7
Medicus Pharma Reports Positive SkinJect Phase 2 Data, Secures $31.9M Capital
Sentiment: Positive
View Wiseek Article
MDCX
Mar 25, 2026, 4:08 PM EDT
Filing Type: 10-K
Importance Score:
9
Medicus Pharma Faces Critical Going Concern Warning Amidst Massive Dilution and Director's Large Selling Plan
Sentiment: Negative
View Wiseek Article
MDCX
Mar 06, 2026, 4:58 PM EST
Filing Type: 424B3
Importance Score:
8
Medicus Pharma Secures $3.85M Through Equity Sales to Yorkville, Reducing Debt and Extending Runway
Sentiment: Neutral
View Wiseek Article
MDCX
Mar 06, 2026, 4:57 PM EST
Filing Type: 424B3
Importance Score:
8
Medicus Pharma Secures $3.85M Through Equity Sales, Prepaying Debt
Sentiment: Neutral
View Wiseek Article
MDCX
Mar 06, 2026, 4:40 PM EST
Filing Type: 8-K
Importance Score:
8
Medicus Pharma Discloses $3.85M Equity Sale, Resulting in Significant Dilution
Sentiment: Negative
View Wiseek Article
MDCX
Mar 05, 2026, 7:30 AM EST
Source: GlobeNewswire
Importance Score:
8
Medicus Pharma's Skin Cancer Drug Achieves 73% Clinical Clearance in Positive Phase 2 Trial
Sentiment: Positive
View Wiseek Article
MDCX
Jan 30, 2026, 4:31 PM EST
Filing Type: S-3
Importance Score:
8
Institutional Investor Registers 4.02M Shares for Resale, Adding Significant Market Overhang
Sentiment: Negative
View Wiseek Article
MDCX
Jan 02, 2026, 10:26 AM EST
Filing Type: 424B5
Importance Score:
9
Medicus Pharma Launches $15.3M At-The-Market Offering, Signaling Critical Need for Capital Amidst Going Concern Warning
Sentiment: Negative
View Wiseek Article